- Home
- ACXP vs PHGE Comparison
ACXP vs PHGE Comparison
Compare ACXP & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- PHGE
- Stock Information
- Founded
- ACXP 2017
- PHGE 2015
- Country
- ACXP United States
- PHGE Israel
- Employees
- ACXP N/A
- PHGE N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- PHGE Health Care
- Exchange
- ACXP Nasdaq
- PHGE Nasdaq
- Market Cap
- ACXP 6.8M
- PHGE 7.8M
- IPO Year
- ACXP 2021
- PHGE N/A
- Fundamental
- Price
- ACXP $4.45
- PHGE $0.28
- Analyst Decision
- ACXP Strong Buy
- PHGE Strong Buy
- Analyst Count
- ACXP 3
- PHGE 1
- Target Price
- ACXP $143.67
- PHGE $15.00
- AVG Volume (30 Days)
- ACXP 75.7K
- PHGE 1.8M
- Earning Date
- ACXP 11-12-2025
- PHGE 11-12-2025
- Dividend Yield
- ACXP N/A
- PHGE N/A
- EPS Growth
- ACXP N/A
- PHGE N/A
- EPS
- ACXP N/A
- PHGE N/A
- Revenue
- ACXP N/A
- PHGE N/A
- Revenue This Year
- ACXP N/A
- PHGE N/A
- Revenue Next Year
- ACXP N/A
- PHGE N/A
- P/E Ratio
- ACXP N/A
- PHGE N/A
- Revenue Growth
- ACXP N/A
- PHGE N/A
- 52 Week Low
- ACXP $3.80
- PHGE $0.25
- 52 Week High
- ACXP $29.40
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- ACXP 41.55
- PHGE 29.35
- Support Level
- ACXP $4.51
- PHGE $0.25
- Resistance Level
- ACXP $5.79
- PHGE $0.29
- Average True Range (ATR)
- ACXP 0.44
- PHGE 0.03
- MACD
- ACXP -0.09
- PHGE -0.01
- Stochastic Oscillator
- ACXP 24.34
- PHGE 20.16
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).